Considerations for Erythema Nodosum Leprosum, with Emphasis on Its Oral Manifestations

Antonio Carlos Vinhas, Roberto Meyer Nascimento

Immunology Institute of Sciences and Health (ICS-UFBA), Salvador, Brazil.
Interactive Processes in Organs and Systems Program, Concentration Area in Biosafety (PPGORGSISTEM), Salvador, Brazil.

DOI: 10.4236/aid.2013.31004                

Abstract

Leprosy is an infectious disease caused by Mycobacterium leprae, transmitted from person to person through contact among susceptible untreated patients. It presents a broad clinical spectrum which is related to the host’s ability to mount a specific immune response. The lesions caused by the proliferation of Mycobacterium leprae (M. leprae) were significantly reduced in recent years with the early detection of new cases. Because they are less evident and/or study, maxillofacial injuries and the oral mucosa may reveal important details about the transmissibility and immunopathogenesis of leprosy. This article was based on a literature to verify an interrelation between oral manifestations in virchowian patients and immuno-pathological factors. Association between the infection of oral mucosa and some pathological findings as well as the participation of the local immune response in protection against the disease are research topics still not fully exploited.

Keywords

Leprosy; Hansen Disease; Oral manifestation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	W. H. Jopling and A. C. McDouglas, “Manual de Hanseníase,” 4th Edition, Atheneu, Rio de Janeiro, 1991, p. 183.
[2]	BRASIL, “Ministério da Saúde. Sistema Nacional de Vigilancia em Saúde,” 5th Edition, Relatório de Situacao, Brasilia, 2011.?
[3]	M. L. F. Penna, “Hanseniase No Brasil: Dados e Indicadores Selecionados,” Ministério da Saúde, Brasília, 2009.
[4]	BRASIL, “Ministério Da Saúde. Departamento de Vigilancia epidemiológica,” Hanseniase No Brasil: Dados e Indicadores Selecionados, Ministério, Brasilia, 2009.
[5]	Secretaria da Saúde, “Saúde Intensifica Combate à Hanseníase em Salvador,” Bahia em Foco, Salvador, 2008.
[6]	BRASIL. Ministério da Saúde. Programa Nacional de Controle da Hanseníase. Brasilia, DF: Ministério, 2008.
[7]	N. Pavloff, “Leprosy in the Nose and Mouth,” Leprosy Review, Vol. 1, No. 2, 1930, pp. 21-25.
[8]	B. M. Prejean, “Manifestations of Leprosy of Interest to the Dentist,” Dental Survey, Vol. 19, No. 6, 1943, pp. 1152-1156.
[9]	L. M. Bechelli and A. Berti, “Les?es Lepróticas Damucosa Bucal: Estudo Clínico,” Revista Brasileira Leprologia, Vol. 7, No. 3, 1039, pp. 187-199.
[10]	H. Leloir, “Etudes Comparèes sur la Lèpre Anatomie Pathologique de la Lèpre,” Comptes Rendus Societe Biologie, Vol. 18, No. 8, 1885, pp. 479-482.
[11]	L. O. Silva, “Tratamento das Localiza??es Leprosas nas vias Aéreas Superiores e na Boca,” Revista Médica de Minas Gerais, Vol. 6, 1038, pp. 9-211.
[12]	B. Mela and L. Casotti, “Sulle Manifestazioni Orali e Mascellari Sulle Leppra,” Rivista italiana di stomatologia, Vol. 1, No. 26, 1939, pp. 755-763.
[13]	I. Lighterman and T. Hidaka, “Leprosy of Oral Cavity and Anexa,” Oral Surgery, Oral Medicine, Oral Pathology, Vol. 15, No. 10, 1962, pp. 1178-1194. doi:10.1016/0030-4220(62)90153-6
[14]	D. Pellegrino, D. V. A. Opromolla and I. Campos, “Lesoes Lepróticas da Cavidade Oral—Sua Importancia Sob O Ponto de Vista Profilático,” Estomatologia e Cultura, Vol. 4, No. 2, 1970.
[15]	R. C. Hastings, “Leprosy,” Medicine in the Tropics, Edinburgh London Melbourne and New York, Vol. 11, No. 9, 1985, pp. 245-246.
[16]	V. K. Sharna, et al., “Tongue Involvement in Lepromatous Leprosy,” International Journal of Dermatology, Vol. 32, No. 1, 1993, pp. 27-29. doi:10.1111/j.1365-4362.1993.tb00957.x
[17]	G. G. Santos, G. Marcucci, L. M. Marchese and J. Guimaraes Jr., “Aspectos Estomatológicos das Lesoes Específicas e N?o-Específicas em Pacientes Portadores da Moléstia de Hansen,” Pesquisa Odontológica Brasileira, Vol. 14, No. 3, 2000, pp. 268-272. doi:10.1590/S1517-74912000000300014
[18]	L. S. Schelinger and M. A. Horwitz, “Complement Receptors and Complement Component C3 Mediate Phagocytosis of Mycobacterium tuberculosis and Mycobacterium leprae,” International Journal of Leprosy, Vol. 58, 1990, pp. 200-201.
[19]	R. G. Talharis Neves, “Dermatologia Tropical: Hanseníase,” Editora Tropical, Manaus, 1997.
[20]	E. O. Rojas, “Macrophages, myeloperoxidase, and Mycobacterium lepraemurium,” Journal of Leukocyte Biology, Vol. 43, No. 5, 1998, pp. 468-470.
[21]	J. A. Cree, et al., “Mucosal Immunity in Leprosy,” International Journal of Leprosy, Vol. 57, No. 4, 1989, p. 318.
[22]	S. J. Lad and P. R. Mahadevan, “Adherence of Mycobacterium leprae to Macrophage as an Indicator of Pathogen Induced Membrane Changes,” Indian Journal of Medical Research, Vol. 76, No. 3, 1982, pp. 804-813.
[23]	R. L. Modlin, et al., “The Innate Immune Response in Leprosy,” Current Opinion in Immunology, Vol. 22, No. 1, 2009, pp. 48-54. doi:10.1016/j.coi.2009.12.001
[24]	S. R. Krutizik, et al., “Activation and Regulation of Toll-Like Cels Receptors 2 and 1 in Human Leprosy,” Nature Medicine, Vol. 9, No. 5, 2003, pp. 525-532. doi:10.1038/nm864
[25]	T. J. Kang, S. B. Lee and G. T. Chae, “A Polymorphism in the Toll-Like Cell Receptor 2 is Associated with IL-12 Production from Monocyte in Lepromatous Leprosy,” Cytokine, Vol. 20, No. 2, 2002, pp. 56-62. doi:10.1006/cyto.2002.1982
[26]	T. J. Kang, et al., “Differential Production of Interleukin-10 and Interleukin-12 in Mononuclear Cells from Leprosy Patients with a Toll-Like Receptor 2 Mutation,” Immunology, Vol. 112, No. 4, 2004, pp. 674-680. doi:10.1111/j.1365-2567.2004.01926.x
[27]	P. Y. Bochud, T. R. Hawn and A. Aderem, “Cutting Edge: a Toll-Like Cell Receptor 2 Polymorphism that is Associated with Lepromatous Leprosy is Unable to Mediate Mycobacterial Signaling,” The Journal of Immunology, Vol. 170, No. 7, 2003, pp. 3451-3454.
[28]	N. M. Shroeder, et al., “High Frequency of Polymorphism Arg753Gln of the Toll-Like Receptor-2 Gene Detected by a Novel Alleles PCR,” Journal of Molecular Medicine, Vol. 81, No. 6, 2003, pp. 368-372.
[29]	D. Montoya, et al., “Divergence of Macrophage Phagocytic and Antimicrobial Programs in Leprosy,” Cell Host Microbe, Vol. 6, No. 4, 2009, pp. 343-353. doi:10.1016/j.chom.2009.09.002
[30]	N. T. Foss, E. B. Oliveira and C. L. Silva, “Correlation between TNF Productions, Increase of Plasma-C-Reactive Protein Level and Supression of T-Lymphocyte Response to Concanavalin A during Erythema Nodosum Leprosum,” Journal of International Leprosy Association, Vol. 61, No. 1, 1993, pp. 218-226.
[31]	E. A. Rivitti and S. A. P. Sampaio, “Dermatologia: Hanseníase,” 1st Edition, Artes Médicas, S?o Paulo, 1998.
[32]	ABUL & ABBAS, A. H. Lichtman and S. P. Jordan, “Imunologia Celular e Molecular Citocinas,” 3rd Edition, Livraria e Editora Revinter, 2000, pp. 256-283.
[33]	T. H. Ottenhoff, “Immunology of Leprosy: Lessons from and for Leprosy,” International Journal of Leprosy and Other Mycobacterial Diseases, Vol. 62, No. 1, 1993, pp. 108-121.
[34]	P. Salgame, et al., “Differing Lymphokine Profiles of Functional Subsets of Human CD 4 and CD 8 T cell clones,” Science, Vol. 254, No. 5029, 1991, pp. 279-282. doi:10.1126/science.1681588
[35]	A. L. Moreira, et al., “Thalidomide Exerts Its Inhibitory Action on Tumor Necrosis Factor Alpha by Enhancing mRNA Degration,” The Journal of Experimental Medicine, Vol. 177, No. 6, 1993, pp. 1675-1680. doi:10.1084/jem.177.6.1675
[36]	N. T. Foss, “Aspectos Imunológicos da Hanseníase,” Medicina, Ribeir?o Preto, Vol. 30, No. 3, 1997, pp. 335-339.
[37]	S. N. Wemambu, et al., “Erythema Nodosum Leprosum: Clinical Manifestation of the Arthus Phenomenon,” Lancet, Vol. 2, No. 7627, 1969, pp. 933-935.
[38]	T. H. M. Ottenhoff and T. Mutis, “Specific Killing of Cytotoxic T Cells and Antigen-Presenting Cells by CD4+ Cytotoxic T Cell Clones. A Novel Potentially Immunoregulatory T-T Cell Interaction in Man,” The Journal of Experimental Medicine, Vol. 171, No. 6, 1990, pp. 2011-2024. doi:10.1084/jem.171.6.2011
[39]	R. L. Modlin, et al., “Lymphocytes Bearing Antigen Specific g/d Receptors Accumulate in Human Infectious Disease Lesions,” Nature, Vol. 339, No. 3, 1989, pp. 544-548. doi:10.1038/339544a0
[40]	G. R. G. Dirksen, H. D. Gründer and M. St?ber, “Guia Brasileiro de Vigilancia Epidemiológica,” 4th Edition, Ministério de Saúde, Brasília, 1988, pp. 1-11.
[41]	BRASIL, “Ministério da Saúde. Guia para o controle da hanseníase,” 2nd Edition, Ministério, Brasilia, 1994, p. 156.